Harvard Bioscience Stock Price, News & Analysis (NASDAQ:HBIO)

$4.70 +0.15 (+3.30 %)
(As of 02/20/2018 04:42 AM ET)
Previous Close$4.55
Today's Range$4.50 - $4.75
52-Week Range$2.25 - $4.85
Volume116,800 shs
Average Volume183,924 shs
Market Capitalization$163.94 million
P/E Ratio-52.22
Dividend YieldN/A
Beta1.39

About Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience logoHarvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company's products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company's product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company's products consist of instruments, consumables and systems that are made up of various individual products.

Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
SectorHealthcare
SymbolNASDAQ:HBIO
CUSIP41690610
Phone+1-508-8938999

Debt

Debt-to-Equity Ratio0.13%
Current Ratio3.40%
Quick Ratio1.87%

Price-To-Earnings

Trailing P/E Ratio-52.2222222222222
Forward P/E Ratio94.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$104.52 million
Price / Sales1.57
Cash Flow$0.18 per share
Price / Cash26.75
Book Value$2.10 per share
Price / Book2.24

Profitability

Trailing EPS($0.09)
Net Income$-4,300,000.00
Net Margins-3.16%
Return on Equity1.11%
Return on Assets0.76%

Miscellaneous

Employees435
Outstanding Shares34,880,000

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings results on Thursday, October, 26th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The medical instruments supplier earned $25.05 million during the quarter, compared to the consensus estimate of $24.60 million. Harvard Bioscience had a positive return on equity of 1.11% and a negative net margin of 3.16%. View Harvard Bioscience's Earnings History.

When will Harvard Bioscience make its next earnings announcement?

Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Harvard Bioscience.

Where is Harvard Bioscience's stock going? Where will Harvard Bioscience's stock price be in 2018?

2 equities research analysts have issued 12-month price objectives for Harvard Bioscience's stock. Their predictions range from $8.00 to $10.00. On average, they anticipate Harvard Bioscience's stock price to reach $9.00 in the next year. View Analyst Ratings for Harvard Bioscience.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a decline in short interest in January. As of January 12th, there was short interest totalling 385,545 shares, a decline of 27.7% from the December 29th total of 533,199 shares. Based on an average daily trading volume, of 95,667 shares, the short-interest ratio is presently 4.0 days. Approximately 1.3% of the shares of the company are short sold.

Who are some of Harvard Bioscience's key competitors?

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the folowing people:

  • James W. Green, Chairman of the Board (Age 57)
  • Jeffrey A Duchemin, President, Chief Executive Officer, Director (Age 49)
  • Robert E Gagnon, Chief Financial Officer (Age 40)
  • Yong Sun, Vice President - Strategic Marketing and Business Development (Age 51)
  • David M. Green, Director (Age 50)
  • Katherine Anne Eade, Independent Director
  • Neal J. Harte, Independent Director (Age 71)
  • John F. Kennedy, Independent Director (Age 67)
  • Thomas W. Loewald, Independent Director (Age 53)

Who owns Harvard Bioscience stock?

Harvard Bioscience's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Heartland Advisors Inc. (4.86%), Royce & Associates LP (4.29%), BlackRock Inc. (4.24%), Segall Bryant & Hamill LLC (2.40%), Foundry Partners LLC (2.10%) and Algert Global LLC (0.54%). Company insiders that own Harvard Bioscience stock include David Green, Earl R Lewis, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.

Who sold Harvard Bioscience stock? Who is selling Harvard Bioscience stock?

Harvard Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Heartland Advisors Inc., BlackRock Inc., Royce & Associates LP and Foundry Partners LLC. View Insider Buying and Selling for Harvard Bioscience.

Who bought Harvard Bioscience stock? Who is buying Harvard Bioscience stock?

Harvard Bioscience's stock was bought by a variety of institutional investors in the last quarter, including Segall Bryant & Hamill LLC, Algert Global LLC, Wells Fargo & Company MN and AXA. Company insiders that have bought Harvard Bioscience stock in the last two years include Earl R Lewis, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

How do I buy Harvard Bioscience stock?

Shares of Harvard Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Harvard Bioscience's stock price today?

One share of Harvard Bioscience stock can currently be purchased for approximately $4.70.

How big of a company is Harvard Bioscience?

Harvard Bioscience has a market capitalization of $163.94 million and generates $104.52 million in revenue each year. The medical instruments supplier earns $-4,300,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis. Harvard Bioscience employs 435 workers across the globe.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON, MA 01746, United States. The medical instruments supplier can be reached via phone at +1-508-8938999 or via email at [email protected]


MarketBeat Community Rating for Harvard Bioscience (HBIO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Harvard Bioscience (NASDAQ:HBIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyN/AN/ABuy
Consensus Rating Score: 3.00N/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00N/AN/A$5.75
Price Target Upside: 106.90% upsideN/AN/A121.15% upside

Harvard Bioscience (NASDAQ:HBIO) Consensus Price Target History

Price Target History for Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ:HBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Janney Montgomery ScottBoost Price TargetBuy -> Buy$5.00 -> $8.00LowView Rating Details
1/23/2018BenchmarkBoost Price TargetBuy -> Buy$6.00 -> $10.00HighView Rating Details
11/17/2016Singular ResearchInitiated CoverageBuy$5.50N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Harvard Bioscience (NASDAQ:HBIO) Earnings History and Estimates Chart

Earnings by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ HBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018$0.05N/AView Earnings Details
10/26/2017Q3 2017$0.03$0.03$24.60 million$25.05 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.03$0.01$24.00 million$25.21 millionViewN/AView Earnings Details
3/9/2017Q4 2016$0.04$0.01$26.90 million$26.42 millionViewListenView Earnings Details
10/27/2016Q3$0.01$0.01$26.00 million$25.01 millionViewListenView Earnings Details
7/28/2016Q2$0.03$0.03$26.60 million$26.10 millionViewListenView Earnings Details
5/12/2016Q1$0.02$0.05$26.00 million$27.00 millionViewListenView Earnings Details
4/29/2016Q4$0.03$0.03$28.37 millionViewN/AView Earnings Details
10/29/2015Q315$0.05$0.03$27.01 million$25.70 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.05$26.60 million$28.80 millionViewListenView Earnings Details
4/30/2015Q414$0.05$0.01$27.15 million$25.80 millionViewListenView Earnings Details
2/26/2015Q314$0.09$0.08$29.30 million$30.40 millionViewN/AView Earnings Details
10/30/2014Q214$0.06$0.05$25.46 million$25.40 millionViewN/AView Earnings Details
7/31/2014Q2$0.05$0.05$26.00 million$26.96 millionViewN/AView Earnings Details
5/1/2014Q1 2014$0.04$25.89 millionViewN/AView Earnings Details
2/27/2014Q413($0.02)$0.05$28.20 million$27.90 millionViewN/AView Earnings Details
10/31/2013Q313$0.01$0.05$26.10 million$25.10 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.01)$26.09 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.08$28.30 million$26.10 millionViewN/AView Earnings Details
2/28/2013Q4 2012$0.02$0.02ViewN/AView Earnings Details
11/1/2012Q312$0.08$26.40 million$26.10 millionViewN/AView Earnings Details
8/2/2012Q2 2012$0.08$0.04ViewN/AView Earnings Details
5/3/2012Q1 2012$0.08$0.04ViewN/AView Earnings Details
3/1/2012Q4 2011$0.08$0.05ViewN/AView Earnings Details
11/3/2011Q3 2011$0.08$0.02ViewN/AView Earnings Details
8/4/2011Q2 2011$0.08$0.07ViewN/AView Earnings Details
4/28/2011Q1 2011$0.10$0.08ViewN/AView Earnings Details
2/25/2011Q4 2010$0.09$0.09ViewN/AView Earnings Details
11/3/2010Q3 2010$0.08$0.11ViewN/AView Earnings Details
8/5/2010Q2 2010$0.09$0.07ViewN/AView Earnings Details
4/29/2010Q1 2010$0.09ViewN/AView Earnings Details
2/25/2010Q4 2009$0.10$0.08ViewN/AView Earnings Details
11/4/2009Q3 2009$0.07$0.05ViewN/AView Earnings Details
8/6/2009Q2 2009$0.04$0.02ViewN/AView Earnings Details
4/30/2009Q1 2009$0.04$0.06ViewN/AView Earnings Details
2/26/2009Q4 2008$0.07$0.06ViewN/AView Earnings Details
11/5/2008Q3 2008$0.06$0.05ViewN/AView Earnings Details
8/11/2008Q2 2008$0.09$0.06ViewN/AView Earnings Details
5/1/2008Q1 2008$0.07$0.07ViewN/AView Earnings Details
2/28/2008Q4 2007$0.08$0.08ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Harvard Bioscience (NASDAQ:HBIO) Earnings Estimates

Current Year EPS Consensus Estimate: $0.05 EPS
Next Year EPS Consensus Estimate: $0.11 EPS

Dividends

Dividend History for Harvard Bioscience (NASDAQ:HBIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Harvard Bioscience (NASDAQ HBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 61.77%
Insider Trades by Quarter for Harvard Bioscience (NASDAQ:HBIO)
Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ HBIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2017Jeffrey DucheminCEOBuy22,000$2.76$60,720.00View SEC Filing  
6/8/2017James W. GreenDirectorBuy7,712$2.55$19,665.60View SEC Filing  
5/26/2017Robert E. GagnonCFOBuy1,000$2.33$2,330.00View SEC Filing  
5/25/2017Earl R. LewisDirectorBuy12,238$2.35$28,759.30View SEC Filing  
5/24/2017Earl R. LewisDirectorBuy10,000$2.38$23,800.00View SEC Filing  
2/7/2017David GreenDirectorSell3,239$3.25$10,526.75View SEC Filing  
2/6/2017David GreenDirectorSell1,288$3.25$4,186.00View SEC Filing  
12/6/2016Earl R. LewisDirectorSell23,088$2.42$55,872.96View SEC Filing  
11/3/2016Jeffrey DucheminCEOBuy15,000$2.42$36,300.00View SEC Filing  
11/3/2016Robert E. GagnonCFOBuy25,000$2.34$58,500.00View SEC Filing  
12/10/2015Jeffrey DucheminCEOBuy10,000$3.37$33,700.00160,210View SEC Filing  
12/3/2015George UvegesDirectorBuy3,000$3.32$9,960.0067,171View SEC Filing  
11/9/2015Robert E GagnonCFOBuy3,000$3.08$9,240.0066,221View SEC Filing  
9/2/2015Jeffrey DucheminCEOBuy2,000$4.41$8,820.00150,210View SEC Filing  
9/1/2015John F KennedyDirectorBuy2,000$4.33$8,660.00177,330View SEC Filing  
7/17/2015David GreenDirectorSell17,103$5.26$89,961.78View SEC Filing  
7/14/2015David GreenDirectorSell51,597$5.28$272,432.16View SEC Filing  
4/23/2015David GreenDirectorSell118,500$6.03$714,555.00View SEC Filing  
4/22/2015David GreenDirectorSell123,997$6.23$772,501.31View SEC Filing  
4/17/2015David GreenDirectorSell42,503$6.55$278,394.65View SEC Filing  
4/14/2015David GreenDirectorSell80,168$6.61$529,910.48View SEC Filing  
2/9/2015David GreenDirectorSell48,712$5.25$255,738.00View SEC Filing  
12/30/2014David GreenDirectorSell16,173$5.25$84,908.25View SEC Filing  
12/29/2014David GreenDirectorSell100,167$5.25$525,876.75View SEC Filing  
12/22/2014David GreenDirectorSell80,202$5.02$402,614.04View SEC Filing  
11/19/2014David GreenDirectorSell10,000$4.95$49,500.00View SEC Filing  
10/31/2014David GreenDirectorSell117,654$4.97$584,740.38View SEC Filing  
6/16/2014Robert E GagnonCFOBuy5,000$3.86$19,300.00View SEC Filing  
5/29/2014Neal J HarteDirectorSell12,317$3.82$47,050.94View SEC Filing  
4/9/2014David GreenDirectorSell27,540$4.47$123,103.80View SEC Filing  
4/8/2014David GreenDirectorSell66,090$4.48$296,083.20View SEC Filing  
4/3/2014David GreenDirectorSell63,501$4.63$294,009.63View SEC Filing  
8/27/2013Chane GrazianoMajor ShareholderBuy60,000$5.00$300,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Harvard Bioscience (NASDAQ HBIO) News Headlines

Source:
DateHeadline
Head to Head Review: Invivo Therapeutics (NVIV) & Harvard Bioscience (HBIO)Head to Head Review: Invivo Therapeutics (NVIV) & Harvard Bioscience (HBIO)
www.americanbankingnews.com - February 12 at 5:12 AM
Harvard Bioscience (HBIO) & Invivo Therapeutics (NVIV) Head to Head ContrastHarvard Bioscience (HBIO) & Invivo Therapeutics (NVIV) Head to Head Contrast
www.americanbankingnews.com - February 9 at 9:10 PM
Waters (WAT) vs. Harvard Bioscience (HBIO) Critical ContrastWaters (WAT) vs. Harvard Bioscience (HBIO) Critical Contrast
www.americanbankingnews.com - February 7 at 1:12 AM
Analyzing Intuitive Surgical (ISRG) & Harvard Bioscience (HBIO)Analyzing Intuitive Surgical (ISRG) & Harvard Bioscience (HBIO)
www.americanbankingnews.com - February 6 at 12:43 PM
Harvard Bioscience closes Data Sciences purchaseHarvard Bioscience closes Data Sciences purchase
seekingalpha.com - January 31 at 8:00 PM
Harvard Bioscience Completes Acquisition of Data Sciences InternationalHarvard Bioscience Completes Acquisition of Data Sciences International
feeds.benzinga.com - January 31 at 7:07 PM
Harvard Bioscience, Inc. (HBIO) Short Interest Down 27.7% in JanuaryHarvard Bioscience, Inc. (HBIO) Short Interest Down 27.7% in January
www.americanbankingnews.com - January 29 at 1:40 AM
Hologic (HOLX) and Harvard Bioscience (HBIO) Critical AnalysisHologic (HOLX) and Harvard Bioscience (HBIO) Critical Analysis
www.americanbankingnews.com - January 27 at 11:26 AM
Neovasc Inc (US) (NVCN) & Harvard Bioscience (HBIO) Head-To-Head SurveyNeovasc Inc (US) (NVCN) & Harvard Bioscience (HBIO) Head-To-Head Survey
www.americanbankingnews.com - January 25 at 10:34 AM
Janney Montgomery Scott Boosts Harvard Bioscience (HBIO) Price Target to $8.00Janney Montgomery Scott Boosts Harvard Bioscience (HBIO) Price Target to $8.00
www.americanbankingnews.com - January 25 at 12:54 AM
Twin Cities lab animal monitoring company to be sold for $70MTwin Cities lab animal monitoring company to be sold for $70M
finance.yahoo.com - January 24 at 9:10 AM
Harvard Bioscience snaps up lab equipment firm for $70MHarvard Bioscience snaps up lab equipment firm for $70M
finance.yahoo.com - January 23 at 4:26 PM
Benchmark Raises Harvard Bioscience (HBIO) Price Target to $10.00Benchmark Raises Harvard Bioscience (HBIO) Price Target to $10.00
www.americanbankingnews.com - January 23 at 9:08 AM
Harvard Bioscience To Acquire Data Sciences International and Sells Denville ScientificHarvard Bioscience To Acquire Data Sciences International and Sells Denville Scientific
finance.yahoo.com - January 22 at 5:25 PM
Head-To-Head Review: Zeltiq Aesthetics (ZLTQ) versus Harvard Bioscience (HBIO)Head-To-Head Review: Zeltiq Aesthetics (ZLTQ) versus Harvard Bioscience (HBIO)
www.americanbankingnews.com - January 13 at 11:26 AM
Analysts Expect Harvard Bioscience, Inc. (HBIO) to Announce $0.05 EPSAnalysts Expect Harvard Bioscience, Inc. (HBIO) to Announce $0.05 EPS
www.americanbankingnews.com - January 13 at 1:38 AM
 Harvard Bioscience, Inc. (HBIO) Given $5.50 Consensus Price Target by Brokerages Harvard Bioscience, Inc. (HBIO) Given $5.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - January 6 at 3:08 AM
Zacks: Brokerages Set $5.50 Price Target for Harvard Bioscience, Inc. (HBIO)Zacks: Brokerages Set $5.50 Price Target for Harvard Bioscience, Inc. (HBIO)
www.americanbankingnews.com - December 26 at 4:07 PM
Zacks: Harvard Bioscience, Inc. (HBIO) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Harvard Bioscience, Inc. (HBIO) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 22 at 5:23 PM
ETFs with exposure to Harvard Bioscience, Inc. : December 18, 2017ETFs with exposure to Harvard Bioscience, Inc. : December 18, 2017
finance.yahoo.com - December 19 at 11:23 AM
Analyzing Harvard Bioscience (HBIO) and Illumina (ILMN)Analyzing Harvard Bioscience (HBIO) and Illumina (ILMN)
www.americanbankingnews.com - December 10 at 1:30 AM
ETFs with exposure to Harvard Bioscience, Inc. : December 7, 2017ETFs with exposure to Harvard Bioscience, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 3:44 PM
 Harvard Bioscience, Inc. (HBIO) Receives Average Recommendation of "Strong Buy" from Analysts Harvard Bioscience, Inc. (HBIO) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - December 6 at 7:24 PM
Analyzing Alere (ALR) & Harvard Bioscience (HBIO)Analyzing Alere (ALR) & Harvard Bioscience (HBIO)
www.americanbankingnews.com - November 23 at 9:36 PM
Analysts Expect Harvard Bioscience, Inc. (HBIO) to Post $0.05 Earnings Per ShareAnalysts Expect Harvard Bioscience, Inc. (HBIO) to Post $0.05 Earnings Per Share
www.americanbankingnews.com - November 17 at 8:40 AM
Harvard Bioscience (HBIO) & The Competition Head-To-Head ContrastHarvard Bioscience (HBIO) & The Competition Head-To-Head Contrast
www.americanbankingnews.com - November 15 at 3:26 AM
Reviewing Harvard Bioscience (HBIO) and Its PeersReviewing Harvard Bioscience (HBIO) and Its Peers
www.americanbankingnews.com - November 12 at 1:10 AM
ETFs with exposure to Harvard Bioscience, Inc. : November 8, 2017ETFs with exposure to Harvard Bioscience, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 6:29 AM
Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 4:38 PM
Comparing Harvard Bioscience (HBIO) and Its CompetitorsComparing Harvard Bioscience (HBIO) and Its Competitors
www.americanbankingnews.com - October 30 at 1:26 PM
Edited Transcript of HBIO earnings conference call or presentation 26-Oct-17 8:30pm GMTEdited Transcript of HBIO earnings conference call or presentation 26-Oct-17 8:30pm GMT
finance.yahoo.com - October 28 at 6:22 AM
Harvard Bioscience, Inc. (HBIO) Announces Quarterly  Earnings Results, Hits ExpectationsHarvard Bioscience, Inc. (HBIO) Announces Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - October 27 at 2:50 PM
Harvard Bioscience (HBIO) Appoints Katherine Eade and Thomas Loewald to the Board of DirectorsHarvard Bioscience (HBIO) Appoints Katherine Eade and Thomas Loewald to the Board of Directors
www.streetinsider.com - October 27 at 3:58 AM
Harvard Bioscience Reports Third Quarter 2017 Financial ResultsHarvard Bioscience Reports Third Quarter 2017 Financial Results
www.thestreet.com - October 27 at 3:58 AM
Harvard Bioscience Appoints Katherine Eade and Thomas Loewald to the Board of DirectorsHarvard Bioscience Appoints Katherine Eade and Thomas Loewald to the Board of Directors
finance.yahoo.com - October 26 at 9:55 AM
Harvard Bioscience, Inc. to Host Earnings CallHarvard Bioscience, Inc. to Host Earnings Call
finance.yahoo.com - October 26 at 9:55 AM
Harvard Bioscience (HBIO) and The Competition Head-To-Head ReviewHarvard Bioscience (HBIO) and The Competition Head-To-Head Review
www.americanbankingnews.com - October 23 at 4:32 AM
ETFs with exposure to Harvard Bioscience, Inc. : October 20, 2017ETFs with exposure to Harvard Bioscience, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 9:14 PM
Harvard Bioscience (HBIO) and Its Rivals Financial ComparisonHarvard Bioscience (HBIO) and Its Rivals Financial Comparison
www.americanbankingnews.com - October 18 at 10:20 PM
Harvard Bioscience Schedules Third Quarter 2017 Conference Call for October 26 at 4:30 PM ETHarvard Bioscience Schedules Third Quarter 2017 Conference Call for October 26 at 4:30 PM ET
feeds.benzinga.com - October 18 at 6:00 PM
ETFs with exposure to Harvard Bioscience, Inc. : October 9, 2017ETFs with exposure to Harvard Bioscience, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 7:29 PM
Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 7:54 PM
Presbia PLC (LENS) versus Harvard Bioscience (HBIO) Head-To-Head ComparisonPresbia PLC (LENS) versus Harvard Bioscience (HBIO) Head-To-Head Comparison
www.americanbankingnews.com - September 23 at 10:26 AM
Reviewing ResMed (RMD) and Harvard Bioscience (HBIO)Reviewing ResMed (RMD) and Harvard Bioscience (HBIO)
www.americanbankingnews.com - August 29 at 10:42 AM
Head to Head Review: Thoratec (THOR) & Harvard Bioscience (HBIO)Head to Head Review: Thoratec (THOR) & Harvard Bioscience (HBIO)
www.americanbankingnews.com - August 19 at 10:48 AM
Edited Transcript of HBIO earnings conference call or presentation 27-Jul-17 8:30pm GMTEdited Transcript of HBIO earnings conference call or presentation 27-Jul-17 8:30pm GMT
finance.yahoo.com - July 29 at 3:07 AM
Harvard Bioscience, Inc. (HBIO) Posts Quarterly  Earnings Results, Misses Expectations By $0.02 EPSHarvard Bioscience, Inc. (HBIO) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - July 28 at 11:33 PM
Harvard Bioscience Reports Second Quarter 2017 Financial ResultsHarvard Bioscience Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 27 at 7:55 PM
Harvard Bioscience Schedules Second Quarter 2017 Conference Call for July 27 at 4:30 PM ETHarvard Bioscience Schedules Second Quarter 2017 Conference Call for July 27 at 4:30 PM ET
finance.yahoo.com - July 18 at 9:19 PM
Harvard Bioscience Schedules Second Quarter 2017 Conference Call for  July 27 at 4:30 PM ETHarvard Bioscience Schedules Second Quarter 2017 Conference Call for July 27 at 4:30 PM ET
feeds.benzinga.com - July 18 at 5:57 PM

SEC Filings

Harvard Bioscience (NASDAQ:HBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Harvard Bioscience (NASDAQ:HBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Harvard Bioscience (NASDAQ HBIO) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.